TY - JOUR
T1 - Cardiovascular Considerations After Cancer Therapy
T2 - Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations
AU - Blaes, Anne
AU - Nohria, Anju
AU - Armenian, Saro
AU - Bergom, Carmen
AU - Thavendiranathan, Paaladinesh
AU - Barac, Ana
AU - Sanchez-Petitto, Gabriela
AU - Desai, Sanjal
AU - Zullig, Leah L.
AU - Morgans, Alicia K.
AU - Herrmann, Joerg
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/1
Y1 - 2025/1
N2 - Cancer survivors, particularly those treated with anthracyclines and chest radiation, face an elevated risk of cancer therapy–related cardiovascular toxicity. These complications affect not only physical health, but also life expectancy. Risk factors for cancer therapy–related cardiovascular toxicity include age at which cancer treatment was received, the use of (potentially) cardiotoxic cancer therapies, and the presence of concomitant cardiovascular risk factors. Current guidelines provide recommendations for cardiovascular surveillance after cancer therapy, including type and frequency. All cancer survivors are advised to undergo annual clinical screenings and optimization of cardiovascular risk factors. Those at higher risk should undergo additional cardiovascular testing. This document aims to summarize the available evidence, present practical recommendations, and outline existent gaps in the current literature regarding cardiovascular care after cancer therapies.
AB - Cancer survivors, particularly those treated with anthracyclines and chest radiation, face an elevated risk of cancer therapy–related cardiovascular toxicity. These complications affect not only physical health, but also life expectancy. Risk factors for cancer therapy–related cardiovascular toxicity include age at which cancer treatment was received, the use of (potentially) cardiotoxic cancer therapies, and the presence of concomitant cardiovascular risk factors. Current guidelines provide recommendations for cardiovascular surveillance after cancer therapy, including type and frequency. All cancer survivors are advised to undergo annual clinical screenings and optimization of cardiovascular risk factors. Those at higher risk should undergo additional cardiovascular testing. This document aims to summarize the available evidence, present practical recommendations, and outline existent gaps in the current literature regarding cardiovascular care after cancer therapies.
KW - 5-fluorouracil
KW - Her2 Therapy
KW - anthracycline
KW - biomarkers
KW - cancer survivorship
KW - cardio-Oncology
KW - cardiotoxicity
KW - coronary artery disease
KW - echocardiography
KW - guidelines
KW - heart Failure
KW - outcomes
KW - scientific statements
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85214329097&partnerID=8YFLogxK
U2 - 10.1016/j.jaccao.2024.06.006
DO - 10.1016/j.jaccao.2024.06.006
M3 - Review article
AN - SCOPUS:85214329097
SN - 2666-0873
VL - 7
SP - 1
EP - 19
JO - JACC: CardioOncology
JF - JACC: CardioOncology
IS - 1
ER -